Alvotech is dedicated to the development and manufacturing of biosimilars, which are biologic medicines designed to improve patient access to affordable treatments. The company employs a vertically integrated approach that spans from research and development (R&D) to fill and finish manufacturing. This strategy allows Alvotech to maintain control over the entire process, ensuring the quality and efficiency of its products. The company focuses on creating a robust pipeline of monoclonal antibodies targeting various therapeutic areas, including immunology, oncology, and ophthalmology. By leveraging strategic partnerships globally, Alvotech aims to enhance the availability of these essential biologic medicines to patients in need.

In its manufacturing operations, Alvotech utilizes state-of-the-art facilities in Reykjavik, Iceland, where single-use technology is employed to minimize the risk of cross-contamination and reduce environmental impact. This technology is complemented by the use of nearly 100% renewable energy sourced locally, aligning with the company's commitment to sustainability. Alvotech is also expanding its drug product capacity to meet future demands while adhering to current Good Manufacturing Practice (cGMP) standards set by regulatory bodies such as the FDA and EMA. This comprehensive approach underscores Alvotech's mission to provide high-quality, cost-competitive biosimilars to patients worldwide.

Iceland

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

Alvotech

Company Details